Laboratory Reference Grade Compounds
← Back to ProtocolsProtocol: gdf-8-1mg

Validated Laboratory Standard

Myology & Hypertrophy Research RegistriesSingle Peptide

GDF-8 / Myostatin Propeptide

Revision 1 · Lyophilized Solid Powder

Endogenous Myostatin Antagonist & Muscle Preservation Probe. Formulated for in-vitro research and laboratory analytical validation.

✓GLP Analytical Monograph & Pharmacological Dossier

GDF-8 / Myostatin Propeptide

Endogenous Myostatin Antagonist & Muscle Preservation Probe. Formulated for in-vitro research and laboratory analytical validation.

≥98.0% (RP-HPLC)Growth Hormone Axis

Pharmacokinetic & Bio-Distribution Parameters (ADME)

Elimination Half-Life (t½)~24 to 48 HoursTypical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
RUO Analytical Standard

Detailed GLP Pharmacological Monograph

Analytical Specification

GDF-8 (Growth Differentiation Factor 8 Propeptide) is the endogenous 243-amino-acid prodomain of myostatin that binds non-covalently to mature myostatin, holding it in a latent, inactive conformation. By preventing myostatin from binding to ActRIIB/ALK4/5 receptor complexes, GDF-8 propeptide halts downstream Smad2/Smad3 phosphorylation, releasing skeletal muscle cells from negative growth constraints in cachexia and sarcopenia assays.

Investigated Pharmacodynamic Endpoints & Cellular Mechanisms

Preclinical Assays
✓
Specific Myostatin Inactivation: Directly binds mature GDF-8 dimers, preventing ActRIIB receptor phosphorylation.
✓
Muscle Fiber Cross-Sectional Area: Promotes satellite cell activation and lean tissue preservation.

Physicochemical Specifications & Analytical Verification

≥98.0% (RP-HPLC)
CAS Number901758-09-6
PubChem CIDCID 92131234 ↗
Molecular Weight27800 g/mol
Primary Sequence / Chemical Formula
Recombinant Human Myostatin Propeptide

Target Solvent

Bacteriostatic Water (0.9% Benzyl Alcohol)

Store refrigerated

Diluent Ratio

1 mL per 1 mg (1 mg/mL)

Slow laminar stream against vial wall; store strictly at -20°C.

Lyophilized Storage

Store at -20°C.

Desiccated and protected from thermal spikes

Liquid Stability

Store at 2°C–8°C.

Refrigerated and light-protected

Pharmacokinetics / Half-Life

~24 to 48 Hours

Typical protocol duration: 8 to 12 Weeks; Washout: 4 Weeks

Preparation, Reconstitution & Syringe Calibration Matrix

Analytical Reference Standard
Select Vial Strength & Volume Configuration:
Dual Reconstitution Standard (1 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake1 mg Active MassVacuum-sealed vial
02
2. Aseptic Diluent1.0 mL DiluentSlowly down vial wall
03
3. Reconstituted Solution1.0 mg/mLGentle circular swirl
04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 10.0 mcg (0.01 mL)
Standard Compound Mass1 mg active per vial
Recommended DiluentBacteriostatic Water (0.9% Benzyl Alcohol)
Diluent Volume Added1.0 mL
Resulting Concentration1.0 mg/mL
Syringe Volumetric ScaleU-100 Syringe (100 units = 1.0 mL | 1 unit = 10.0 mcg (0.01 mL))

Interactive Syringe Calibration & Reconstitution Stoichiometry— GDF-8 / Myostatin Propeptide

Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.

U-100 Micro-Plunger
1. Compound Mass1 mg
mg
Vials:
2. Diluent Volume1.0 mL
mL
Quick:
3. Target Assay Dose10.0 Units
Presets:
Dissolution Vial
1.0 mg/mL1.0 mL
1mg / 1mL
Syringe: 100 U (1.0 mL Workhorse)
10.0 Units (0.100 mL)
010203040506070809010010.0 U
0 U100 U
💡Micro-Dose Accuracy: Low draw (10.0 U). A 30 U (0.3 mL) barrel provides 3× optical tick resolution.
Selected Dose
100 mcg
0.100 mg active mass
Injection Volume
0.100 mL
100 µL draw
U-100 Syringe Mark
10.0 Units
Barrel Graduation
Single Vial Yield
~10.0 Doses
10 days at 1x Daily

Clinical Trial Titration & Escalation Schedules

Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.

Analytical Titration Schedule•Target: GDF-8 / Myostatin Propeptide•1x Daily
Escalation Stage & PhaseTarget DoseU-100 Mark (1mg / 1.0mL)CadenceSyringe Sync
In-Vitro Assay Titration Schedule (Weeks 1–2)50 mcg5.0 Units(0.05 mL)1x Daily
In-Vitro Assay Titration Schedule (Weeks 3–8)100 mcg10.0 Units(0.10 mL)1x Daily
In-Vitro Assay Titration Schedule (Weeks 9+)200 mcg20.0 Units(0.20 mL)1x Daily
Reagent & Consumables Supply Inventory PlanningBased on 1mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 1.5 mg
Active Vials (1mg):2 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 3.9 mg
Active Vials (1mg):5 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 10.0 Units (0.10 mL)
Research DoseVolume (mL)U-100 Syringe Graduation Mark
50 mcg0.050 mL5 Units
5 units
100 mcg0.10 mL10 Units
10 units
200 mcg0.20 mL20 Units
20 units
Calibrated Administration Instrument & Needle Hardware Specification
RUO Standard
Aliquoting Needle
×
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
Sterile diluent transfer down glass wall

U-100 Insulin Syringe (0.3 mL, 31G)

Target: 10.0 IU = 100 mcg at 1.0 mg/mL
Research DoseCalibrated VolumeU-100 Syringe UnitsGraduation Description
50 mcg0.05 mL (50 µL)5 Units5 units
100 mcg0.1 mL (100 µL)10 Units10 units
200 mcg0.2 mL (200 µL)20 Units20 units
💉

Syringe Barrel Resolution & Dead-Space Calculator

ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering

5 U-100 Units (0.05 mL)
Mass @ 1.0 mg/mL:50 mcg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard
✓ Exact Tick Mark Alignment (5 Units)
0102030
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 16.7% of barrel
Tick Increment
0.5 Unit (5 µL)
Volumetric step
Low-Dead-Space (LDS)
<0.4 µL (0.79%)
Integrated needle waste
Measurement Error
±1.5%
ISO 8537 tolerance
Needle Configuration
31G (0.26mm)
5/16" (8mm) length
⚖️

Critical Dead-Space Compound Preservation Analysis (GDF-8 / Myostatin Propeptide)

Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.

Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 0.4 µL
Wastage per Titration:0.79% of dose
84-Day Cumulative Loss:0.034 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:52.4% of dose
84-Day Cumulative Loss:4.62 mg (Multiple Vials!)
Barrel CapacityGraduation IntervalVolume per TickHub Dead-SpaceNeedle SpecSuitability for 5 Units
0.3 mL (30 Units)BEST FIT0.5 Unit5 µL (0.005 mL)< 0.4 µL31G × 5/16" (8mm) Integrated Ultra-Fine✓ Accommodates 5 units
0.5 mL (50 Units)1 Unit10 µL (0.010 mL)< 0.8 µL30G–31G × 5/16" (8mm) Integrated✓ Accommodates 5 units
1 mL (100 Units)2 Unit20 µL (0.020 mL)< 2.1 µL29G–30G × 1/2" (12.7mm) Integrated✓ Accommodates 5 units
📏 Parallax Error Elimination SOP

Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.

📐 Analytical Dispensing Angle & Vessel Depth

Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.

12-Week Clinical Research Supply & Protocol Forecast

Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for GDF-8 / Myostatin Propeptide.

Active Compound
1.50 mg
Across 12 weeks (12 doses)
Vials Required
2 × 1mg
Includes 8% dead-space buffer
Bacteriostatic Water
1 × 10 mL Bottle
2.0 mL total diluent
Sterile Syringes
18 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
36 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)

Do NOT reconstitute all 2 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.

WeekStudy / Assay PhaseWeekly Target DoseSyringe Draw (U-100)Active Vial #Cumulative Active Mass
Week 1Initiation (Weeks 1–2)50 mcg5 Units(0.05 mL)Vial #1(0.95mg rem)0.1 mg / 1.5 mg
Week 2Initiation (Weeks 1–2)50 mcg5 Units(0.05 mL)Vial #1(0.9mg rem)0.1 mg / 1.5 mg
Week 3Target Regimen (Weeks 3–8)100 mcg10 Units(0.10 mL)Vial #1(0.8mg rem)0.2 mg / 1.5 mg
Week 4Target Regimen (Weeks 3–8)100 mcg10 Units(0.10 mL)Vial #1(0.7mg rem)0.3 mg / 1.5 mg
Week 5Target Regimen (Weeks 3–8)100 mcg10 Units(0.10 mL)Vial #1(0.6mg rem)0.4 mg / 1.5 mg
Week 6Target Regimen (Weeks 3–8)100 mcg10 Units(0.10 mL)Vial #1(0.5mg rem)0.5 mg / 1.5 mg
Week 7Target Regimen (Weeks 3–8)100 mcg10 Units(0.10 mL)Vial #1(0.4mg rem)0.6 mg / 1.5 mg
Week 8Target Regimen (Weeks 3–8)100 mcg10 Units(0.10 mL)Vial #1(0.3mg rem)0.7 mg / 1.5 mg
Week 9Intensive Regimen (Weeks 9+)200 mcg20 Units(0.20 mL)Vial #1(0.1mg rem)0.9 mg / 1.5 mg
Week 10Intensive Regimen (Weeks 9+)200 mcg20 Units(0.20 mL)Vial #2(0.8mg rem)1.1 mg / 1.5 mg
Week 11Intensive Regimen (Weeks 9+)200 mcg20 Units(0.20 mL)Vial #2(0.6mg rem)1.3 mg / 1.5 mg
Week 12Intensive Regimen (Weeks 9+)200 mcg20 Units(0.20 mL)Vial #2(0.4mg rem)1.5 mg / 1.5 mg
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030

In-Vitro Assay Titration Schedule

Assay Schedule

Study duration: 8 to 12 Weeks · Washout: 4 Weeks

Period / PhaseTarget AmountFrequencyNotes & Calibration
Weeks 1–2Starting Baseline50 mcg
Weekly
Initiation: Myostatin binding baseline (5 units on U-100 syringe)
Weeks 3–8100 mcg
Weekly
Target Regimen: Smad2/3 pathway suppression (10 units on U-100 syringe)
Weeks 9+200 mcg
Weekly
Intensive Regimen: Maximal myofibrillar protein synthesis (20 units on U-100 syringe)

Investigated Research Endpoints & Observed Mechanisms

Biological Properties
✓Specific Myostatin Inactivation: Directly binds mature GDF-8 dimers, preventing ActRIIB receptor phosphorylation.
✓Muscle Fiber Cross-Sectional Area: Promotes satellite cell activation and lean tissue preservation.

Adverse Observations, Handling Precautions & In-Vitro Sensitivities

Laboratory Safety Notes
!Potential Tendon Adaptation Stress: Rapid muscle expansion requires connective tissue monitoring.

Preparation and Handling SOP

Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water (0.9% Benzyl Alcohol). Slow laminar stream against vial wall; store strictly at -20°C.

Physicochemical Stability & Reconstituted Storage

Environmental Guidelines
Lyophilized Solid Powder
Store at -20°C.
Reconstituted Solution
Store at 2°C–8°C.
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️

Physicochemical Thermostability & Environmental Tolerance Matrix

4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for GDF-8 / Myostatin Propeptide

USP <659> Packaging & Storage
💧

Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)

Operating Window: +2°C to +8°C (36°F to 46°F)

State: Reconstituted Solution28 to 35 Days

Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).

Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
  • ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
  • ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
  • ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
Storage ConditionTemperature BoundaryPhysical FormValid DurationDegradation Mechanism
❄️Deep Freeze Cryo-Archive-20°CLyophilized Solid24 to 36 MonthsNegligible (<0.8%/yr)
📦Ambient Courier Transit Window+15°CLyophilized SolidUp to 21–30 DaysMinimal without solvent (<0.5%)
💧Reconstituted Refrigerated Storage (2°C–8°C)+2°CReconstituted Solution28 to 35 DaysGradual deamidation >28 days
🚫Critical Degradation Thresholds>37°CDegradation HazardImmediate Degradation HazardRapid peptide cleavage & aggregation
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.

Storage and Biohazard Disposal

Store at Store at -20°C.. Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.

Scholarly Research Citations (1 References)

Peer-Reviewed Index

Frequently Asked Questions

How should GDF-8 / Myostatin Propeptide be reconstituted?

Slow laminar stream against vial wall; store strictly at -20°C.

What is the estimated laboratory half-life of GDF-8 / Myostatin Propeptide?

GDF-8 / Myostatin Propeptide displays an estimated half-life of ~24 to 48 Hours. Typical study protocols run for 8 to 12 Weeks followed by a washout period of 4 Weeks.

Pharmacological Profile and Mechanism

GDF-8 (Growth Differentiation Factor 8 Propeptide) is the endogenous 243-amino-acid prodomain of myostatin that binds non-covalently to mature myostatin, holding it in a latent, inactive conformation. By preventing myostatin from binding to ActRIIB/ALK4/5 receptor complexes, GDF-8 propeptide halts downstream Smad2/Smad3 phosphorylation, releasing skeletal muscle cells from negative growth constraints in cachexia and sarcopenia assays.

Aseptic Reconstitution Procedure

1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution. 2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe. 3. Diluent Addition: Using a sterile syringe, slowly draw 1 mL of Bacteriostatic Water (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side. 4. Gentle Dissolution: Slow laminar stream against vial wall; store strictly at -20°C. 5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. undefined

Storage and Temperature Stability

Lyophilized powder: Store at -20°C.. Once reconstituted: Store at 2°C–8°C.. Keep shielded from UV light.

Physicochemical Specifications

CAS Number: 901758-09-6 PubChem CID: 92131234 Formula/Sequence: Recombinant Human Myostatin Propeptide Molecular Weight: 27800 g/mol

In-Vitro Concentration & Assay Schedule

• Initiation (Weeks 1–2): Target Assay Dose: 50 mcg weekly | Cadence: Weekly Assay Focus: Myostatin binding baseline Volumetric Calibration: 5 units on U-100 syringe • Target Regimen (Weeks 3–8): Target Assay Dose: 100 mcg weekly | Cadence: Weekly Assay Focus: Smad2/3 pathway suppression Volumetric Calibration: 10 units on U-100 syringe • Intensive Regimen (Weeks 9+): Target Assay Dose: 200 mcg weekly | Cadence: Weekly Assay Focus: Maximal myofibrillar protein synthesis Volumetric Calibration: 20 units on U-100 syringe Typical Study Duration: 8 to 12 Weeks Receptor Washout Window: 4 Weeks
Available in Catalog

GDF-8 / Myostatin Propeptide (1mg Research Vial)

High-purity lyophilized laboratory reference formulation with certified Certificate of Analysis (COA).

View Product in Catalog →
Strictly for in vitro and academic laboratory research purposes only. Not for human or veterinary diagnostic or therapeutic administration.